Routes to making life-saving medications and other pharmaceutical compounds are among the most carefully protected trade secrets in global industry. Building on recent work programming computers to identify synthetic pathways leading to pharmaceutically complex molecules, researchers in Poland and South Korea have unveiled computerized methods to suggest only synthetic strategies that bypass patent-protected aspects of essential drugs.
Their work appears January 17 in the journal Chem.
“When we started this project, I was somewhat skeptical that the machine would find any viable synthetic alternatives–after all, these are blockbuster drugs worth gazillions of dollars, and I was sure that the respective companies had covered the patent space so densely that no loopholes remained,” says senior author Bartosz Grzybowski, a professor of chemistry at the Ulsan National Institute of Science and Technology (South Korea) and the Polish Academy of Sciences and the lead developer of the organic synthesis software Chematica. “It turns out that the loopholes are there, and we can find new retrosynthetic pathways that circumvent the patents entirely.”
Those pharmaceutical patents protect the company’s intellectual property while also preventing competitor companies from using certain key synthetic solutions–developed painstakingly by experiment to maximize yield, increase purity, and reduce costs–when attempting to produce desired compounds. To get to viable unpatented options, the researchers “froze” challenging portions of each target molecule, forcing the computer to substitute unconventional yet chemically plausible approaches on the basis of mechanistic rules. They tested their system out on three notable commercial medicines with different chemical hurdles: linezolid, a last-resort antibiotic; sitagliptin, an antidiabetic drug; and panobinostat, a multiple myeloma treatment.
In each case, when allowed to run without constraints, the program recommended the commercial syntheses. But when even a few atoms and bonds were designated as untouchable, it innovated by applying Chematica’s existing functions to propose new plans that neatly avoided those already patented. “By algorithmically locating the key bonds on which patents hinge and propagating them down Chematica’s retrosynthetic trees, we can generate synthetic solutions from alternative yet economical starting materials, achieving a real practical impact,” Grzybowski says.
Chematica’s patent-dodging abilities could also alter how chemists approach intellectual property and patent law. For example, machine-aided searches could be used to restrict many different parts of a target molecule, lumping radically different syntheses into a single airtight patent. According to Grzybowski, however, such a patent would not necessarily stay loophole-free forever, thanks to the likely future experimental discovery of novel reactions driving chemical knowledge forward through healthy competition.
Overall, the researchers hope that their software will aid pharmaceutical companies in better protecting their intellectual property and, simultaneously, will help accelerate research and development in organic chemistry by supplying synthetic routes that differ from standard approaches. “This work illustrates the benefits of pushing chemists to think algorithmically and asking computer scientists to grasp key chemical concepts, delivering chemical artificial intelligence results that matter beyond the confines of academia,” adds co-author Piotr Dittwald, a research fellow with training in mathematics and computer science.
The Latest on: Pharma patents
via Google News
The Latest on: Pharma patents
- Full Fed. Circ. Skips Biogen Fight Over MS Drug Patenton June 24, 2020 at 7:20 pm
Biogen lost another bid on Wednesday to ward off competition for its blockbuster multiple sclerosis drug Tecfidera, as the full Federal Circuit said it wouldn't reconsider a panel decision that Banner ...
- Generic colonoscopy prep-maker wins round in patent caseon June 24, 2020 at 5:17 am
Generic drugmaker Lupin Inc’s instructions for using its proposed colonoscopy-prep solution do not induce patients or physicians to infringe Ferring Pharmaceuticals’ patent on administering name-brand ...
- Top UK Court Invalidates Regeneron's Lab Mice Patentson June 24, 2020 at 5:16 am
The U.K.'s highest court has invalidated two of Regeneron's patents for genetically modifying research mice, ruling on Wednesday that patents must include enough detail for someone else to reproduce ...
- Titan Pharmaceuticals And Indegene Enter Into Probuphine® Co-Promotion Partnershipon June 24, 2020 at 5:00 am
SAN FRANCISCO, June 24, 2020 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has entered into a co-promotion partnership with Indegene Inc ...
- Patent pool initiative in Japan aims to share covid-19 vaccineson June 23, 2020 at 5:21 am
An initiative proposed by Prime Minister Shinzo Abe aims to share production methods of vaccines and therapeutic drugs to cope with the novel coronavirus worldwide under the framework of a patent pool ...
- House Dems introduce bill to prevent big pharma price-gouging during COVID-19 Pandemicon June 22, 2020 at 3:50 pm
The legislation was applauded as necessary to combat Trump’s “sycophancy to drug corporations” that is “endangering the nation’s pandemic response.” On the heels of polling that showed 88% of ...
- COVID-19 puts a spotlight on the Medicines Patent Poolon June 22, 2020 at 4:26 am
As it approaches its 10th birthday, the pool is attracting attention for its model of making patented medicines more affordable in lower-income countries.
- WPD Pharmaceuticals Licensor Announces Confirmatory in Vitro Analysis of WP1122on June 22, 2020 at 4:00 am
WPD Pharmaceuticals Inc. (CSE: WBIO ) (FSE: 8SV1) (the " Company " or " WPD "), a clinical stage pharmaceutical company, is pleased to announce that Moleculin Biotech Inc. (" Moleculin "), the company ...
- Hisun Pharmaceutical: Free of COVID-19, Governments Suggest Favipiraviron June 22, 2020 at 3:43 am
PRNewswire/ -- Favipiravir is a broad-spectrum antiviral agent that inhibits the RNA-dependent RNA polymerase of RNA viruses. It has efficacy against a ...
- Nobel laureate Honjo sues Ono Pharmaceutical over patent royaltieson June 19, 2020 at 11:44 pm
Japanese Nobel laureate in medicine Tasuku Honjo has filed a lawsuit against Ono Pharmaceutical Co, seeking about 22.6 billion yen ($211 million) in patent royalties from the company that sells the ...
via Bing News